Drug used to treat parkinsonism. Adverse effects include anorexia, gastrointestinal disturbances, and movement disorders.
A naturally occurring amino acid administered by mouth to treat parkinsonism. Common side-effects are nausea, vomiting, loss of appetite, and involuntary facial movements; high doses may cause weakness, faintness, and dizziness.
A drug used in the treatment of parkinsonism. It is converted to dopamine in the brain, correcting the deficiency which causes the disorder. Levodopa is often given with carbidopa or benserazide both dopamine decarboxylase inhibitors to prevent its conversion to dopamine in the body before it reaches the brain. It may cause nausea, hypotension or cardiac dysrhythmia.
A precursor of dopamine that readily crosses the blood-brain barrier into the central nervous system (CNS), where it is converted to dopamine. L-dopa is used to treat parkinson’s disease in which there is deficiency of dopamine caused by the progressive deterioration of dopamine-producing neurons in the substantia nigra of the midbrain.
A natural chemical that stimulates the production of dopamine in the brain and is used to treat Parkinson’s disease.
A medication employed in the management of Parkinson’s disease, levodopa is capable of traversing the blood-brain barrier, a safeguard for the brain. Once within the brain, it undergoes conversion into dopamine, thereby replenishing the dopamine that is depleted in individuals with Parkinson’s disease.
A medication employed for the management of Parkinson’s disease. Typically, levodopa is partnered with carbidopa or benserazide, compounds that amplify the impact of levodopa while mitigating its adverse effects, such as nausea, vomiting, unease, and restlessness.